Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models

被引:41
|
作者
Catlin, N. R. [1 ]
Bowman, C. J. [1 ]
Campion, S. N. [1 ]
Cheung, J. R. [1 ]
Nowland, W. S. [1 ]
Sathish, J. G. [3 ]
Stethem, C. M. [1 ]
Updyke, L. [2 ]
Cappon, G. D. [1 ]
机构
[1] Pfizer Worldwide Res Dev & Med, Eastern Point Rd,MS 8274-1260, Groton, CT 06340 USA
[2] Pfizer Worldwide Res Dev & Med, Cambridge, MA 02139 USA
[3] Pfizer Worldwide Res Dev & Med, Pearl River, NY 10965 USA
关键词
Nirmatrelvir; NMV; PAXLOVID; Coronavirus; COVID-19; Embryo-Fetal development; Fertility; Genetic toxicity; Rat; Rabbit; Oral COVID-19 therapy; RIBAVIRIN;
D O I
10.1016/j.reprotox.2022.01.006
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nirmatrelvir (PF-07321332; NMV) the antiviral component of PAXLOVID (TM) is a potent and selective inhibitor of the SARS-CoV-2 main protease (M-pro), which plays a critical role in viral replication. PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a pharmacokinetic enhancer), is an oral therapy currently in development as a therapeutic option for those infected with SARS-CoV-2 to prevent progression to severe disease, hospitalization, and death. PAXLOVID has been shown to be efficacious against hospitalization and death in two Phase 2/3 clinical studies that evaluated non hospitalized patients both with and without high risk factors for progression to severe illness. Given that males and females of reproductive age are included in the intended patient population, we assessed the potential effects of NMV up to the limit dose of 1000 mg/kg/day in ICH guideline embryo-fetal development studies in rats and rabbits, and a fertility and early embryonic development study in rats. There were no effects on male and female fertility or early embryonic development in rats, and no severe manifestations of developmental toxicity in rats or rabbits. The lack of adverse findings reported here in nonclinical species is consistent with the intended therapeutic target of NMV (a virus specific protein not present in mammalian cells), the favorable off-target selectivity profile, and lack of genetic toxicity. The results of these nonclinical studies with NMV along with existing ritonavir safety information indicate that there are no clinically relevant risks associated with PAXLOVID administration during pregnancy and in males and females of reproductive age.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 50 条
  • [21] An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
    Owen, Dafydd R.
    Allerton, Charlotte M. N.
    Anderson, Annaliesa S.
    Aschenbrenner, Lisa
    Avery, Melissa
    Berritt, Simon
    Boras, Britton
    Cardin, Rhonda D.
    Carlo, Anthony
    Coffman, Karen J.
    Dantonio, Alyssa
    Di, Li
    Eng, Heather
    Ferre, RoseAnn
    Gajiwala, Ketan S.
    Gibson, Scott A.
    Greasley, Samantha E.
    Hurst, Brett L.
    Kadar, Eugene P.
    Kalgutkar, Amit S.
    Lee, Jack C.
    Lee, Jisun
    Liu, Wei
    Mason, Stephen W.
    Noell, Stephen
    Novak, Jonathan J.
    Obach, R. Scott
    Ogilvie, Kevin
    Patel, Nandini C.
    Pettersson, Martin
    Rai, Devendra K.
    Reese, Matthew R.
    Sammons, Matthew F.
    Sathish, Jean G.
    Singh, Ravi Shankar P.
    Steppan, Claire M.
    Stewart, Al E.
    Tuttle, Jamison B.
    Updyke, Lawrence
    Verhoest, Patrick R.
    Wei, Liuqing
    Yang, Qingyi
    Zhu, Yuao
    SCIENCE, 2021, 374 (6575) : 1586 - +
  • [22] Animal models for SARS-CoV-2
    Lee, Chung-Young
    Lowen, Anice C.
    CURRENT OPINION IN VIROLOGY, 2021, 48 : 73 - 81
  • [23] Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
    Robert M. Cox
    Carolin M. Lieber
    Josef D. Wolf
    Amirhossein Karimi
    Nicole A. P. Lieberman
    Zachary M. Sticher
    Pavitra Roychoudhury
    Meghan K. Andrews
    Rebecca E. Krueger
    Michael G. Natchus
    George R. Painter
    Alexander A. Kolykhalov
    Alexander L. Greninger
    Richard K. Plemper
    Nature Communications, 14
  • [24] Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
    Cox, Robert M.
    Lieber, Carolin M.
    Wolf, Josef D.
    Karimi, Amirhossein
    Lieberman, Nicole A. P.
    Sticher, Zachary M.
    Roychoudhury, Pavitra
    Andrews, Meghan K.
    Krueger, Rebecca E.
    Natchus, Michael G.
    Painter, George R.
    Kolykhalov, Alexander A.
    Greninger, Alexander L.
    Plemper, Richard K.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [25] Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations
    Tam, Nguyen Minh
    Nguyen, Trung Hai
    Pham, Minh Quan
    Hong, Nam Dao
    Tung, Nguyen Thanh
    Vu, Van V.
    Quang, Duong Tuan
    Ngo, Son Tung
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 124
  • [26] Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
    Chatterjee, Srijan
    Bhattacharya, Manojit
    Dhama, Kuldeep
    Lee, Sang-Soo
    Chakraborty, Chiranjib
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2023, 32 : 263 - 266
  • [27] Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
    Preschel, H. Daniel
    Otte, Ruben T.
    Zhuo, Ying
    Ruscoe, Rebecca E.
    Burke, Ashleigh J.
    Kellerhals, Rachel
    Horst, Brendan
    Hennig, Sven
    Janssen, Elwin
    Green, Anthony P.
    Turner, Nicholas J.
    Ruijter, Eelco
    JOURNAL OF ORGANIC CHEMISTRY, 2023, 88 (17): : 12565 - 12571
  • [28] Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
    Tong, Xiao
    Keung, Walter
    Arnold, Lee D.
    Stevens, Laura J.
    Pruijssers, Andrea J.
    Kook, Seunghyi
    Lopatin, Uri
    Denison, Mark
    Kwong, Ann D.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (11)
  • [29] Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19
    Ghosh, Arun K.
    Yadav, Monika
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2023, 21 (28) : 5768 - 5774
  • [30] Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 Mpro
    Citarella, Andrea
    Moi, Davide
    Pedrini, Martina
    Perez-Pena, Helena
    Pieraccini, Stefano
    Stagno, Claudio
    Micale, Nicola
    Schirmeister, Tanja
    Sibille, Giulia
    Gribaudo, Giorgio
    Silvani, Alessandra
    Passarella, Daniele
    Giannini, Clelia
    MOLECULES, 2023, 28 (02):